Wednesday's Early Winners & Losers

Vascular Solutions (VASC Quote) surged more than 20% in after-hours trading Tuesday after the medical-supplies maker announced that the FDA had approved its D-Stat Flowable hemostat product for a new use.

For patients implanted with pulse generators -- pacemakers and ICDs, or implantable cardioverter defibrillators -- D-Stat, a thick suspension of collagen, thrombin and diluent, can coat the pocket created in the prepectoral area (between the fat tissue and the breast muscle) where the device is embedded. This pocket, especially under the influence of anticoagulants to prevent blood clots, tends to bleed for significant lengths of time following implantation; this, in turn, leads to a pocket hematoma (or a clotty collection of blood) that can eventually cause infection. The coating, says Minneapolis-based Vascular, helps to cut down on hematoma formation. D-Stat was previously approved for topical applications in 2002. Shares were trading up $1.56 to $9.12.

Bisys Group (BSG Quote), a New Jersey-based fund administrator that recently settled kickback charges with the Securities and Exchange Commission, rose on reports that it is now considering a management buyout. A few months ago, mulling the possibility of selling the company, Bisys hired a Bear Stearns analyst to evaluate that option. A buyout now appears to be the more likely course of action, according to those familiar with the discussions. Shares were up 39 cents, or 3.1%, to $13.01.